中国医药导刊
中國醫藥導刊
중국의약도간
CHINESE JOURNAL OF MEDICAL GUIDE
2013年
2期
311
,共1页
阿托伐他汀%急性心肌梗死%介入治疗
阿託伐他汀%急性心肌梗死%介入治療
아탁벌타정%급성심기경사%개입치료
Atorvastatin%Acute myocardial infarction%Interventional therapy
目的:探讨阿托伐他汀早期强化疗法在急性心肌梗死(AMI)介入治疗术后(PCI)患者中的临床应用价值.方法:将106例行PCI治疗的AMI患者随机分为观察组和对照组各53例,观察组采用大剂量阿托伐他汀强化治疗,对照组采用常规剂量治疗.结果:治疗后两组TC及LDL-C水平均有明显下降,与治疗前比较有显著性差异(P<0.05),观察组下降更为明显,组间比较有显著性差异(P<0.05);观察组共发生主要不良心血管事件4例,对照组共发生7例,两组比较有显著性差异(P<0.05).结论:对PCI术后的AMI患者采用早期强化治疗剂量的阿托伐他汀,能显著改善患者的血脂水平,降低主要不良心血管事件的发生率,值得临床推广.
目的:探討阿託伐他汀早期彊化療法在急性心肌梗死(AMI)介入治療術後(PCI)患者中的臨床應用價值.方法:將106例行PCI治療的AMI患者隨機分為觀察組和對照組各53例,觀察組採用大劑量阿託伐他汀彊化治療,對照組採用常規劑量治療.結果:治療後兩組TC及LDL-C水平均有明顯下降,與治療前比較有顯著性差異(P<0.05),觀察組下降更為明顯,組間比較有顯著性差異(P<0.05);觀察組共髮生主要不良心血管事件4例,對照組共髮生7例,兩組比較有顯著性差異(P<0.05).結論:對PCI術後的AMI患者採用早期彊化治療劑量的阿託伐他汀,能顯著改善患者的血脂水平,降低主要不良心血管事件的髮生率,值得臨床推廣.
목적:탐토아탁벌타정조기강화요법재급성심기경사(AMI)개입치료술후(PCI)환자중적림상응용개치.방법:장106례행PCI치료적AMI환자수궤분위관찰조화대조조각53례,관찰조채용대제량아탁벌타정강화치료,대조조채용상규제량치료.결과:치료후량조TC급LDL-C수평균유명현하강,여치료전비교유현저성차이(P<0.05),관찰조하강경위명현,조간비교유현저성차이(P<0.05);관찰조공발생주요불양심혈관사건4례,대조조공발생7례,량조비교유현저성차이(P<0.05).결론:대PCI술후적AMI환자채용조기강화치료제량적아탁벌타정,능현저개선환자적혈지수평,강저주요불양심혈관사건적발생솔,치득림상추엄.
Objective:Effects of atorvastatin on early intensive therapy in acute myocardial infarction (AMI) after interventional therapy (PCI) patients in clinical application.Methods:106 cases of PCI treated by AMI were randomly divided into the observation group and the control group with 53 cases in each group,the observation group was treated with high dose atorvastatin treatment,the control group using conventional dose therapy.Results:After treatment in the two groups TC and LDL-C levels were significantly decreased compared with those before treatment,there were significant differences (P<0.05),the observation group decreased more significantly,compared between groups with significant difference (P<0.05);the observation group were major adverse cardiovascular events in 4 cases,control group with 7 cases,two groups have significant differences ( P<0.05).Conclusion:On PCI patients with AMI after treatment with early intensive atorvastatin,can significantly improve the patient's lipid levels,reduced major adverse cardiovascular event rates,worthy of clinical application.